Abstract
Acquired drug resistance is a major limitation for successful treatment of cancer. Resistance emerges due to drug exclusion, drug metabolism and alteration of the drug target by mutation or overexpression. Depending on therapy, the type of cancer and its stage, one or several genetic or epigenetic alterations are necessary to confer resistance to treatment. The fundamental question is the following: if a genetically diverse population of replicating cancer cells is subjected to chemotherapy that has the potential to eradicate it, what is the probability of emergence of resistance? Here, we review a general mathematical framework based on multi-type branching processes designed to study the dynamics of escape of replicating organisms from selection pressures. We apply the general model to evolution of resistance of cancer cells and discuss examples for diverse mechanisms of resistance. Our theory shows how to estimate the probability of success for any treatment regimen.
Keywords: Cancer Therapy, Evolution of Resistance, Evolutionary Dynamics
Current Pharmaceutical Design
Title: Evolution of Resistance to Cancer Therapy
Volume: 12 Issue: 3
Author(s): Franziska Michor, Martin A. Nowak and Yoh Iwasa
Affiliation:
Keywords: Cancer Therapy, Evolution of Resistance, Evolutionary Dynamics
Abstract: Acquired drug resistance is a major limitation for successful treatment of cancer. Resistance emerges due to drug exclusion, drug metabolism and alteration of the drug target by mutation or overexpression. Depending on therapy, the type of cancer and its stage, one or several genetic or epigenetic alterations are necessary to confer resistance to treatment. The fundamental question is the following: if a genetically diverse population of replicating cancer cells is subjected to chemotherapy that has the potential to eradicate it, what is the probability of emergence of resistance? Here, we review a general mathematical framework based on multi-type branching processes designed to study the dynamics of escape of replicating organisms from selection pressures. We apply the general model to evolution of resistance of cancer cells and discuss examples for diverse mechanisms of resistance. Our theory shows how to estimate the probability of success for any treatment regimen.
Export Options
About this article
Cite this article as:
Michor Franziska, Nowak A. Martin and Iwasa Yoh, Evolution of Resistance to Cancer Therapy, Current Pharmaceutical Design 2006; 12 (3) . https://dx.doi.org/10.2174/138161206775201956
DOI https://dx.doi.org/10.2174/138161206775201956 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insights on Melatonin as an Active Pharmacological Molecule in Cancer Prevention: What’s New?
Current Medicinal Chemistry A Critical and Comprehensive Insight on Heme Oxygenase and Related Products Including Carbon Monoxide, Bilirubin, Biliverdin and Ferritin in Type-1 and Type-2 Diabetes
Current Pharmaceutical Design Bio-analytical Identification of Key Genes that Could Contribute to the Progression and Metastasis of Osteosarcoma
Current Bioinformatics 5-Fluorouracil Derivatives Induce Differentiation Mediated by Tubulin and HLA Class I Modulation
Medicinal Chemistry C-Met Inhibitors are Potential Novel Therapeutic Agents Against Listeria monocytogenes Infection Through Blocking the Bacteria Entry into Nonphagocytic Cells
Current Topics in Medicinal Chemistry Almonds: A Source of Healthy Molecules or a Risk of Aflatoxins Human Exposure?
Current Nutrition & Food Science Nano Conjugated PLGA-Chlorambucil: Synthesis In Vitro Anti Non- Hodgkin's Lymphoma Cellular Assay
Letters in Drug Design & Discovery Review of Clinic Trials: Agents Targeting c-Met
Reviews on Recent Clinical Trials Next Generation Tyrosine Kinase Inhibitor (TKI): Afatinib
Recent Patents on Anti-Cancer Drug Discovery Porphyrins in Photodynamic Therapy - A Search for Ideal Photosensitizers
Current Medicinal Chemistry - Anti-Cancer Agents Ghrelin and Energy Balance: Focus on Current Controversies
Current Drug Targets Recent Advance in the Design of Small Molecular Modulators of Estrogen-Related Receptors
Current Pharmaceutical Design Targeting the RAS Signaling Pathway in Malignant Hematologic Diseases
Current Drug Targets Targeting the Immune System in Cancer
Current Pharmaceutical Biotechnology Imino-Sugar-Based Nucleosides
Current Topics in Medicinal Chemistry Chemoinformatics Approaches for Traditional Chinese Medicine Research and Case Application in Anticancer Drug Discovery
Current Drug Discovery Technologies Recent Progress in Mutation-driven Therapy, Immunotherapy and Combination Therapy for the Treatment of Melanoma
Current Cancer Drug Targets Cyclophilin A as a Target of Cisplatin Chemosensitizers
Current Cancer Drug Targets The Development of Medications for Alcohol-Use Disorders Targeting the GABAB Receptor System
Recent Patents on CNS Drug Discovery (Discontinued) Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors
Current Topics in Medicinal Chemistry